Forma Therapeutics
Improving the lives of people with diabetes and other chronic conditions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $1.1b Valuation: $1.1b 172.8x EV/Revenue -6.9x EV/EBITDA | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (2500 %) |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | - | - | (2371 %) |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Forma Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing transformative medicines for patients with rare hematologic diseases and cancers. The company operates in the biopharmaceutical sector, focusing on innovative drug discovery and development. Forma Therapeutics serves patients, healthcare providers, and the broader medical community by addressing unmet medical needs with novel therapeutic solutions. The business model revolves around research and development, clinical trials, and eventual commercialization of its drug candidates. Revenue is primarily generated through partnerships, licensing agreements, and future product sales. Forma Therapeutics emphasizes patient-centric approaches, integrating patient and community insights into their scientific endeavors to ensure impactful outcomes.
Keywords: biopharmaceutical, clinical-stage, transformative medicines, rare diseases, hematologic, cancers, drug discovery, patient-centric, innovation, therapeutic solutions.